A+| A| A-

An Unethical and Unwarranted Assurance

The Government of India gives "private assurances" to its friends in Big Pharma in the United States.

The compulsory licence is the definitive instrument in the amended Patents Act of 2003 that ensures that there is a way out in case patented products go out of reach of the sick and the needy. Specifically, compulsory licence provisions award manufacturing rights to Indian pharma companies if a patent on a medicine is not worked in India, or if the medicine is expensive, and/or if the patent holder is not able to meet the reasonable requirements of those needing the medicine in India. The Indian manufacturer, Natco, got a compulsory licence awarded to it for Bayer’s sorafenib tosylate, used in certain kinds of renal and liver cancers, in accordance with these provisions. At the time, Bayer’s price for this drug in India was Rs 2,88,425 per person per month while Natco’s was Rs 8,800 per person per month. Novartis was selling its anti-cancer drug imatinib mesylate at a high price of Rs 1.2 lakh per month per patient (Rs 40,000 per 10 tablets) during the days it was arguing before the Indian courts on the drug’s patent worthiness. The patent was denied on considerations of Section 3(d) of the Patents Act. The Rajasthan Medical Services Corporation’s recent procurement price of imatinib 400 mg tablets is almost 1,400 times less at Rs 29 per 10 tablets.

These developments are not welcome tidings for bodies like the US–India Business Council (USIBC). Its president famously has declaimed in his report of February 2016 that feeds into this year’s Special 301 review of the United States Trade Representative (USTR):

To read the full text Login

Get instant access

New 3 Month Subscription
to Digital Archives at

₹826for India

$50for overseas users

Comments

(-) Hide

EPW looks forward to your comments. Please note that comments are moderated as per our comments policy. They may take some time to appear. A comment, if suitable, may be selected for publication in the Letters pages of EPW.

Using ordinance to protect freedom of expression from foul speech may result in damaging decent communication.

Only an empowered regulator can help boost production and cut coal imports.

Biden’s policy of the “return to the normal” would be inadequate to decisively defeat Trumpism.

*/ */

Only a generous award by the Fifteenth Finance Commission can restore fiscal balance.

*/ */

The assessment of the new military alliance should be informed by its implications for Indian armed forces.

The fiscal stimulus is too little to have any major impact on the economy.

The new alliance is reconfigured around the prospect of democratic politics, but its realisation may face challenges.

A damning critique does not allow India to remain self-complacent on the economic and health fronts.

 

The dignity of public institutions depends on the practice of constitutional ideals.

The NDA government’s record in controlling hunger is dismal despite rising stocks of cereal.

 

Back to Top